Canaccord lowered the firm’s price target on Health Catalyst (HCAT) to $9 from $10 and keeps a Buy rating on the shares. The firm said while they are lowering their 2Q estimates, their 2025 forecasts are only modestly tweaked. Clearly, there remains uncertainty given the macro environment, but managementindicated confidence in a growing pipeline of new business opportunities to reach its bookings target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Health Catalyst’s Strong Q1 Performance and Strategic Platform Transition Justify Buy Rating
- Health Catalyst Reports Strong Q1 2025 Results
- Health Catalyst: Strong Q1 Performance and Promising Growth Outlook Drive Buy Rating
- Health Catalyst reports Q1 adjusted EPS 1c, consensus 0c